Theme: Organic Pharmacy Industry
Applications: Therapeutic development
Partnerships and awards: Winner of I-Lab and Hodefi 2020 Obtained Orphan Drug Designation
Laboratory: OncoThAI Unit U1189
Institutions: LILLE UNIVERSITY HOSPITAL / INSERM/ University of Lille
Technology
Combination of a photosensitizing pharmacological agent and the use of laser light to eliminate tumor cells while preserving healthy tissue
Applications
This photoactivatable drug aims to significantly prolong the survival of patients with glioblastoma, one of the most aggressive forms of brain cancer.
Benefits
This technology minimizes surgical risk and limits the risk of tumor recurrence, which is currently very high.
Maturity
July 2023: Hemerion obtains approval from the US Food and Drug Administration (FDA) to launch its clinical trial for the treatment of glioblastoma, the most aggressive form of brain cancer.
For more information
Contact your dedicated advisor